Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Author(s):
Vojdeman, F.J.; Herman, S.E.M.; Kirkby, N.; Wiestner, A.; t' Veer, M.B. van; Tjonnfjord, G.E.; Itala-Remesg, M.A.; Kimby, E.; Farooqui, M.Z.; Polliack, A.; Wu, K.L.; Doorduijn, J.K.; Alemayehu, W.G.; Wittebol, S.; Kozak, T.; Walewski, J.; Abrahamse-Testroote, M.C.J.; Oers, M.H.J. van; Geisler, C.H.; Niemann, C.U.
Published
2017
Publication type
Article / Letter to editor
CD52CLLchemo-immunotherapyibrutinib
Date issued
2017-12-31
Language
English
Is part of
Leukemia & Lymphoma (2017), Vol. 58, no. 10, p. 2356-2362
hdl
1887/115117
doi
10.1080/10428194.2017.1285027